Topics

Companies Related to "Lack significant pharmacokinetic interaction between letermovir calcineurin inhibitors" [Most Relevant Company Matches] RSS

16:53 EST 21st February 2020 | BioPortfolio

Here are the most relevant search results for "Lack significant pharmacokinetic interaction between letermovir calcineurin inhibitors" found in our extensive corporate database of over 50,000 company records.

Showing "Lack significant pharmacokinetic interaction between letermovir calcineurin inhibitors" Companies 1–25 of 1,300+

Relevant

Amura Holdings Ltd

Amura has two complementary technology platforms which enable rapid and innovative drug discovery. AMcore™, the bicyclic core molecular scaffold chemistry and the computational screening and design platform, ProtoDiscovery™. Amura has four NCE discovery programmes based on AMcore™:An Osteoporosis programme based on cathepsin K inhibitors, A Psoriasis programme based on a cathepsin S inhibit...


CalciMedica, Inc.

CalciMedica is the leading biopharmaceutical company focused on calcium release-activated calcium (CRAC) channels and dedicated to the discovery and development of novel drugs for the treatment of autoimmune and inflammatory diseases. The primary focus of the Company's drug discovery effort is based on the specific inhibition of CRAC channels, a key component of the ICRAC-NFAT pathway. The ICRAC-N...

KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. is a pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. The initial focus is on inhibitors of plasma kallikrein, which is an important component of the body’s inflammatory response and which, in excess, can l...


HQL Pharmaceuticals Ltd.

Based in Rehovot, Israel, HQL Pharmaceuticals (www.hql.co.il) is a Biotech company that utilizes its proprietary computational technology to fundamentally change the way drug discovery is conducted. HQL's revolutionary CSS™ computational technology enables highly efficient screening of chemical libraries of more than 20 orders of magnitude higher than...

Repetitive strain injury (RSI)

Repetitive strain injury (RSI) is an umbrella term for many separate ailments affecting the hand, wrist, arm, neck, upper back, and shoulder. Medical professionals also use the phrases "occupational overuse injuries" or "cumulative trauma disorders" for this condition, which can result from intensive hand use (see risk factors for RSI).Symptoms of RSI include numbness, tingling, lack of endurance,...

Prolexys Pharmaceuticals, Inc.

Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company’s therapeutic focus is on cancer and cardiovascular indications where Prolexys has identified novel, druggable therapeutic targets. Small molecules that act at these targets have been identified and tested in cell and animal models of diseas...

Step Pharma

Step Pharma is focused on the development of a novel class of oral nucleotide synthesis inhibitors targeting CTPS1 for the improved treatment of a range of autoimmune diseases. The company has identified several series of CTPS1 inhibitors, with the most advanced series currently undergoing lead optimization.

Viamet Pharmaceuticals, Inc.

Viamet discovers and develops novel inhibitors of key metalloenzymes via an innovative and proprietary metal-binding approach, the Metallophile™ Technology. Viamet’s disruptive Metallophile™ Technology is based on world-class expertise in bioinorganic chemistry and metalloenzymes and allows Viamet to identify metalloenzyme targets with high therape...

Amura Therapeutics Ltd

Amura has two complementary technology platforms which enable rapid and innovative drug discovery. AMcore™, the bicyclic core molecular scaffold chemistry and the computational screening and design platform, ProtoDiscovery™. Amura has four NCE discovery programmes based on AMcore™: An Osteoporosis programme based on cathepsin K inhibitors A Psoriasis programme based on a cathepsin S inhibit...

Forbius

Forbius is a clinical stage company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases. Forbius’ medicines are designed to radically transform patients’ lives. We use our strength in biological understanding and diverse protein engineering technologies to design superior inhibitors of validated pathways. W...

Inflection Biosciences Ltd

Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises the IBL-300 series (PIM/PI3K/mTOR inhibitors) and IBL-202 (PIM/PI3K inhibito...

Euclises Pharmaceuticals, Inc.

Euclises Pharmaceuticals, Inc. (Euclises) is a drug discovery and development company focused on novel cyclooxygenase-2 (COX-2) inhibitors for use in the oncology setting. Euclises has developed a portfolio of COX-2 inhibitors optimized for cancer treatment based on its proprietary Euclicoxib® platform and is in the process of selecting a lead clinical ...

Atheer

Atheer is the pioneer in Augmented interactive Reality (AiR), combining the power of 3D augmented reality with gesture-based interaction to unlock human productivity. Atheer’s innovations herald a new-era of computer-human interaction and present an immersive computing canvas at your fingertips anytime, anywhere. The company is based in Mountain View,...

PolyTherics

PolyTherics is a private UK biotech company that provides technology solutions to enable the development of better biopharmaceuticals. PolyTherics has developed proprietary technologies for the site-specific conjugation of polymers, such as polyethylene glycol (PEG), to any therapeutic peptide or protein, including antibodies, antibody fragments and protei...

Sequoia Pharmaceuticals, Inc.

Sequoia Pharmaceuticals discovers and develops revolutionary new treatments for viral diseases including HIV/AIDS and HCV-induced hepatitis with a focus on the growing global problem of drug-resistant infectious diseases. Most anti-infective drugs were designed to block the most prevalent form of a pathogen. Those drugs are doomed to become obsolete due to the emergence of drug-resistant mutations...

InterAction

Innocrin Pharmaceuticals, Inc.

Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer. VT-464 and the entire CYP17 inhibitor patent estate are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as we...

Interaction Associates

Probably Relevant

Lux Biosciences, Inc.

Lux Biosciences, Inc. is a privately held biotechnology company focused on the treatment of ophthalmic diseases. Lux Biosciences has exclusive worldwide rights to voclosporin for all ophthalmic indications and is cooperating with the team at Isotechnika Pharma who discovered the molecule. For more information on Lux Biosciences, please visit the companyâ...

FlightBridgeED and Life Link III

FlightBridgeED, LLC is a medical education company that specializes in providing pre-hospital, critical care, and emergency medicine education for healthcare professionals of all types. Initially, we were created out of what several air medical industry professionals observed as a terrible lack of education for paramedics wanting to step onto a skid, and into the skies. Of course, once the conver...

Proteolix, Inc.

Founded in December 2003, Proteolix, Inc. is a privately-held biotechnology company, headquartered in South San Francisco, dedicated to discovering, developing and commercializing novel therapeutics that target protein degradation pathways for cancer and autoimmune diseases. Proteolix's lead product, carfilzomib, is the first in a new class of selective, irreversible proteasome inhibitors. Prote...

Bioavailability Systems, LLC

BAS was founded in 1996 by James W. Harris, PhD and Robert A. Baugher as a limited liability company incorporated in Maryland. The company's goal was to pursue the identification and commercialization of active anti- First Pass Effect components in grapefruit. In 1997 Dr. Harris successfully isolated compounds from grapefruit demonstrated to be highly active through in-vitro tests as human CYP 3A ...

OncoImmunin Incorporated

OncoImmunin, Inc. was founded by Dr. Akira Komoriya and Dr. Beverly Packard in 1994. The Company has been issued two U.S. patents on its proprietary design for protease inhibitors and fluorogenic substrates. The first PCT application has now entered into national phases in Japan and Europe and a second PCT was filed in 1998.OncoImmunin, Inc. has designed, synthesized, validated, and patented a new...

TopoGEN, Inc

TopoGEN, Inc. provides innovative reagents and kits for topoisomerase research and mechanism-based drug development. Kits are available to assay for topoisomerases (I, II, IV and gyrase) and Tdp1, to assay for topo inhibition in cells and to characterize topoisomerase inhibitors. DNA substrates, topo inhibitors, antibodies, and kit replacement reagents are also available. Products are listed in o...

OncoImmunin, Inc

OncoImmunin, Inc. was founded by Dr. Akira Komoriya and Dr. Beverly Packard in 1994. The Company has been issued three U.S. patents and one Australian patent on its proprietary design for protease inhibitors and fluorogenic substrates. Multiple new applications as well CIP and PCT applications are under review.OncoImmunin, Inc. has designed, synthesized, validated, and patented a new class of prot...


More From BioPortfolio on "Lack significant pharmacokinetic interaction between letermovir calcineurin inhibitors"

Quick Search

Corporate Database Quicklinks